...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers.
【24h】

Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers.

机译:在健康志愿者中以200 mg和400 mg薄膜衣片形式给药的地昔洛芬的药代动力学。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The pharmacokinetic properties of 2 film-coated preparations containing 200 mg and 400 mg dexibuprofen were compared in a single-dose, crossover study in 16 healthy, male volunteers. Dexibuprofen was absorbed rapidly (tmax 2.1 - 2.2 hours) reaching maximum concentrations of 12.4 microg/ml (200 mg), respectively 12.0 microg/ml (400 mg dose adjusted). For the characteristics AUC(0-12h) and AUC(0-infinity) arithmetic means of 49.2 (microg) x (h/ml)(200 mg) and 48.2 (microg) x (h/ml)(400 mg dose-adjusted), respectively 50.5 (microg) x (h/ml)(200 mg), and 49.2 (microg) x (h/ml)(400 mg) were calculated. No relevant differences for the pharmacokinetic characteristics terminal half-life, clearance, volume of distribution, and mean residence time were observed. A linear dose-relationship was shown over the investigated dose range. Mean ratios after dosage adjustment of the test preparation using the "2 one-sided t-tests" procedure were calculated. Bioequivalence was assessed for AUC(0-12h) with a mean ratio of 97.7% (90% CI: 92.4 - 103.3%), for AUC(0-infinity) with 97.1% (90% CI: 91.4 - 103.1%), and for Cmax with 97.5% (90% CI: 91.7 - 103.8%). Both dexibuprofen preparations were well tolerated. No changes in hematological and biochemical parameters were detected.
机译:在16名健康男性志愿者的单剂量,交叉研究中,比较了2种含有200 mg和400 mg地昔布洛芬的薄膜包衣制剂的药代动力学特性。 Dexibuprofen快速吸收(tmax 2.1-2.2小时)达到最大浓度分别为12.4 microg / ml(200 mg)和12.0 microg / ml(400 mg调整剂量)。对于特征AUC(0-12h)和AUC(0-无穷大),算术平均值为49.2(微克)x(h / ml)(200毫克)和48.2(微克)x(h / ml)(400毫克剂量调整) )分别计算为50.5(微克)x(h / ml)(200毫克)和49.2(微克)x(h / ml)(400毫克)。没有观察到药代动力学特征的半衰期,清除率,分布体积和平均停留时间有相关差异。在研究的剂量范围内显示线性剂量关系。在使用“ 2个单侧t-检验”程序调整测试制剂的剂量后,计算平均比率。评估了AUC(0-12h)的生物等效性,其平均比率为97.7%(90%CI:92.4-103.3%),AUC(0-infinity)的生物等效性为97.1%(90%CI:91.4-103.1%),并且Cmax值为97.5%(90%CI:91.7-103.8%)。两种昔布洛芬制剂均耐受良好。没有检测到血液和生化参数的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号